ABI 007.
ABI 007 is an albumin-stabilised nanoparticle formulation of paclitaxel designed to overcome insolubility problems encountered with paclitaxel. This then eliminates the need for toxic solvents like cremophor, which limits the dose of paclitaxel that can be administered and hence effect overall drug efficacy. ABI 007 is being developed for the treatment of a variety of tumour types by American Pharmaceutical Partners. In addition to the standard infusion formulation of ABI 007, oral and pulmonary delivery formulations are also being investigated. American Pharmaceutical Partners, a subsidiary of American BioScience, secured exclusive North American marketing and manufacturing rights to ABI 007 from American BioScience in November 2001. American BioScience completed a phase III study in the US in metastatic breast cancer patients in early 2003. An indication for which ABI 007 was granted fast track status in January 2003. The phase III study directly compared the efficacy of ABI 007 260 mg/m(2) with paclitaxel 175 mg/m(2). Both agents were administered every 3 weeks. ABI 007 was administered as a 30-minute infusion without steroid pretreatment. Paclitaxel-treated patients received steroid pretreatment and the drug was administered over 3 hours. In October 2002, a Data Monitoring Committee concluded that a sample size adjustment of the phase III trial would not be required and that the study can be continued to completion. Enrolment was completed in December 2002 with 460 first- and second-line metastatic breast cancer patients enrolled. The results were expected to be unblinded in mid-2003. A phase II trial of ABI 007 is also underway in metastatic breast cancer patients who have failed taxane therapy. The trial is evaluating a weekly rather than 3-weekly regimen of ABI 007. Earlier, in May 2003, American Pharmaceutical Partners reported that ABI 007 is also being evaluated for the treatment of non-small cell lung cancer, ovarian cancer, melanoma and cervical cancers. However, the phase of development for these indications remains unclear.
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D001943:Breast Neoplasms / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007269:Injections, Intra-Arterial; D017239:Paclitaxel; D043823:Taxoids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D017239:Paclitaxel